Broad bean (Vicia faba) consumption and Parkinson's disease: A natural source of L-dopa to consider;Consumo de habas (Vicia faba) y enfermedad de Parkinson: Una fuente natural de L-dopa a tener en cuenta

Neurologia

Volumn 30, Issue 6, 2015, Pages 375-391

  Ramirez Moreno J M ^a   Salguero Bodes, I ^a   Romaskevych, O ^a   Duran Herrera, M C ^a  

^a HOSPITAL INFANTA CRISTINA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA; ANTIPARKINSON AGENT;

FOOD INTAKE; LETTER; PARKINSON DISEASE; VICIA FABA; ADVERSE EFFECTS; AGED; CASE REPORT; FOOD DRUG INTERACTION; HUMAN; MALE; MEDICINAL PLANT;

AGED; ANTIPARKINSON AGENTS; FOOD-DRUG INTERACTIONS; HUMANS; LEVODOPA; MALE; PARKINSON DISEASE; PLANTS, MEDICINAL; VICIA FABA;

EID: 84937639485     PISSN: 02134853     EISSN: 15781968     Source Type: Journal    
DOI: 10.1016/j.nrl.2013.08.006     Document Type: Letter

References (8)

1. Raguthu L., Varanese S., Flancbaum L., Tayler E., di Rocco A. Fava beans and Parkinson's disease: Useful 'natural supplement' or useless risk?. Eur J Neurol 2009, 16:e171.
2. Guggenheim M. Dioxyphenylalanina, a new amino acid from Vicia faba. Z Physiol Chem 1913, 88:276.
3. Vered Y., Rabey J.M., Palevitch D., Grosskopf I., Harsat A., Yanowski A., et al. Bioavailability of levodopa after consumption of Vicia faba seedlings by Parkinsonian patients and control subjects. Clin Neuropharmacol 1994, 17:138-146.
4. Apaydin H., Ertan S., Ozekmekçi S. Broad bean (Vicia faba)--a natural source of L-dopa--prolongs «on» periods in patients with Parkinson's disease who have «on-off» fluctuations. Mov Disord 2000, 15:164-166.
5. Kempster P.A., Bogetic Z., Secombei J.W., Martin H.D., Balazs N.D.H., Wahlqvist M.L. Motor effects of broad beans (Vicia faba) in Parkinson's disease: Single dose studies. Asia Pacific J Clin Nutr 1993, 2:85-89.
6. Rabey J.M., Vered Y., Shabtai H., Graff E., Korczyn A.D. Improvement of parkinsonian features correlate with high plasma levodopa values after broad bean (Vicia faba) consumption. J Neurol Neurosurg Psychiatry 1992, 55:725-727.
7. Nutt J.G. Long-term L-dopa therapy: Challenges to our understanding and for the care of people with Parkinson's disease. Exp Neurol 2003, 184:9-13.
8. Clavero-Ibarra P., Gil-Alzueta M.C. Abordaje práctico de las discinesias en la enfermedad de Parkinson. Rev Neurol 2012, 54(Supl 5):S33-40.